Brink Biologics, Inc. (BBI) is a NantKwest Inc. (NASDAQ: NK) affiliated biotechnology solutions company located in the prestigious Torrey Pines biotechnology science park in San Diego, CA. BBI makes available Neukopanel®, a standardized panel of CD16 expressing NK-92® cell lines that provide for the first time the means to establish a consistent, robust and reliable assay for assessment of ADCC activity. Brink Biologics, Inc. holds the exclusive non-clinical rights to the NK-92®️ cell line and its CD16 expressing derivatives, all of which are uniquely and ideally suited for antibody-dependent cell-mediated cytotoxicity (ADCC) assays. BBI offers next-generation bioanalytical testing services and enablement in the rapidly expanding field of cell-based functional assays. Antibody dependent cell-mediated cytotoxicity (ADCC) assays that employ Brink Biologics' Neukopanel® are based on the highly regarded NK-92® cell line platform, which BBI exclusively licenses from NantKwest Inc. for non-clinical laboratory based applications. BBI’s NK-92® based cell line products are produced under stringent conditions, are offered with a certificate of analysis and are suitable for basic science research, GLP laboratory applications as well as in the testing and release of clinical grade products. BBI’s platform is presently in use across many top-tier pharmaceutical and biotechnology companies as well as newly emerged biotech companies across the globe.